Failure of tofacitinib to achieve an objective response in a DDX3X-MLLT10 T-lymphoblastic leukemia with activating JAK3 mutations. Wong, J, Wall M, Corboy GP, Taubenheim N, Gregory GP, Opat S, Shortt J. Cold Spring Harb Mol Case Stud. 2020; 6(4): a004994.
A consensus statement on the use of biosimilar medicines in haematology in Australia. Gregory GP, Carrington C, Cheah CY, Hawkes EA, Irving IM, Siderov J, Opat S. Asia-Pac J Clin Oncol. 2020; 16(4):211-221.
Excellent outcomes of transformed lymphomas in the rituximab era without autologous stem cell transplantation: an Australian, single-centre experience. Tedjaseputra A, Gilbertson M, Low M, Fedele PL, Kumar B, Simpson I, Grigoriadis G, Shortt J, Opat S, Gregory GP*. Intern Med J. 2020 [in press]. *Senior author.
Distinct and overlapping mechanisms of resistance to azacytidine and guadecitabine in acute myeloid leukemia Gruber, E., Franich, R. L., Shortt, J., Johnstone, R. W. & Kats, L. M., Leukemia. 2020, 34, 3388-3392
Prolonged administration of low-dose cytarabine and thioguanine in elderly patients with acute myeloid leukaemia (AML) achieves high complete remission rates and prolonged survival. Arthur, C., Jeffrey, A., Yip, E., Katsioulas, V., Nalpantidis, A., Kerridge, I., Greenwood, M., Coyle, L., Mackinlay, N., Fay, K., Enjeti, A., Shortt, J. & Stevenson, W. Leukemia and Lymphoma. 20 Mar 2020, 61, 4, p. 831-839.
Rapid and durable complete remission of refractory AITL with azacitidine in absence of TET2 mutation or concurrent MDS. Gregory GP, Dickinson M, Yannakou CK, Wong J, Blombery P, Corboy G, Kats L, Crozier TME, Kumar B, Prince HM, Opat SS, Shortt J. HemaSphere April 2019, Volume 3, Issue 2, p. e187
Epithelial-mesenchymal plasticity in breast cancer model systems: Implications for metastatic progression of clinical breast cancer. Waltham, M. C. Clinical and Experimental Metastasis. Apr 2019, 36, 2, p. 147-147.
Human-specific RNA analysis shows uncoupled epithelial-mesenchymal plasticity in circulating and disseminated tumour cells from human breast cancer xenografts. Tachtsidis, A., Le, A. V-P., Blick, T., Gunasinghe, D., De Sousa, E., Waltham, M., Dobrovic, A. & Thompson, E. W. Clinical and Experimental Metastasis. 15 Aug 2019, 36, 4, p. 393-409.
Most clinical anti-EGFR antibodies do not neutralize both wtEGFR and EGFRvIII activation in glioma Greenall, S. A., McKenzie, M., Seminova, E., Dolezal, O., Pearce, L., Bentley, J., Kuchibhotla, M., Chen, S. C., McDonald, K. L., Kornblum, H. I., Endersby, R., Adams, T. E. & Johns, T. G. Neuro-Oncology, 1 Aug 2019, 21, 8, p. 1016-1027.
Tumour Lysis Syndrome. MacLeod R, van den Block L, (eds). Gregory GP, Shortt J. Textbook of Palliative Care 2018. Springer, Cham.
Differential Sensitivity of Human Hepatocellular Carcinoma Xenografts to an IGF-II Neutralizing Antibody May Involve Activated STAT3. Greenall, S. A., Donoghue, J., Johns, T. G. & Adams, T. E. Translational Oncology. 1 Aug 2018, 11, 4, p. 971-978.
Plasma Cell-Free DNA (cfDNA) Concentration and Outcomes in Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Patients Treated with Androgen Receptor Signalling Inhibitors (ARSIs). Fettke, H., Kwan, E., Mant, A., Docanto, M., Bukczynska, P., To, S., Waltham, M. C., Ng, N., Parente, P., Pezaro, C. & Azad, A. Asia-Pacific Journal of Clinical Oncology. Mar 2018, 14, S2, p. 29-29, abs15.
Down-regulation of a pro-apoptotic pathway regulated by PCAF/ADA3 in early stage gastric cancer Daniella Brasacchio, Rita A. Busuttil, Tahereh Noori, Ricky W. Johnstone , Alex Boussioutas, and Joseph A. Trapani. Cell Death Dis. 2018 May; 9(5): 442.
BET-bromodomain inhibitors engage the host immune system and regulate the expression of the immune checkpoint ligand PDL1. Hogg SJ, Vervoort SJ, Deswal S, Ott CJ, Li J, Cluse LA, Beavis PA, Darcy PK, Martin BP, Spencer A, Sadovnik I, Bauer K, Valent P, Traunbauer AK, Bradner JE, Zuber J, Shortt J*& Johnstone RW*. Cell Rep 2017; 18: 2162-74. *co-senior authors.
A chemical probe toolbox for dissecting the cancer epigenome. Shortt J*, Ott CJ*, Johnstone RW & Bradner JE. Nat Rev Cancer 2017; 17: 160-83. *co-first authors.
Epigenetic control of mitochondrial cell death through PACS1-mediated regulation of BAX/BAK oligomerization. Brasacchio D et al. Cell Death and Differentiation 2017; 24: 961–970.
LPP3 mediates self-generation of LPA gradients by melanoma cells. Journal of Cell Science. Susanto O, Koh YW, Morrice N, van den Broek N, Tumanov S, Thomason PA, Nielson M, Tweedy L, Muinonen-Martin AJ, Kamphorst JJ, Mackay GM, Insall RH. 2017, 130(20):3455-3466.
IgD attenuates the IgM-induced anergy response in treanisional and mature B cells. Sabouri Z, Perotti S, Spierings E, Humburg P, Yabas M, Bergmann H, Horikawa K, Roots C, Lambe S, Young C, Andrews TD, Field M, Enders A, Reed JH, Goodnow CC. Nat Commun 2016; 7: 13381.
CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive Myc-driven lymphoma in vivo. Gregory GP…. Johnstone RW* & Shortt J*. Leukemia 2015; 29: 1437-41. *equal contributions.